Start date


End date



Laura Ordovás

Funding agency

Gobierno de Aragón. SGI 171-466

Cardiovascular disease is the leading cause of dead in occidental countries and aging is a major risk factor predisposing to it. The adult heart has nearly no regenerative capacity to repair ischemic damage or to prevent the deleterious effects of aging. MicroRNAs have shown regenerative capacity and a role on aging. The overall objective of DIANA is to develop highly translational and innovative cardio-selective nanotherapies to treat heart disease and aging. Specifically, it aims to create novel advanced therapies based on therapeutic miR or anti-miR that selectively act in the heart by leveraging cutting-edge DNA nanotechnology.